NCT07865117Recruiting
Development of a Digital Personalised Nutrition Tool for Adolescents Undergoing Cancer Treatment
Digital Innovation for Personalised Nutrition in Adolescent Oncology
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This study aims to develop and test MybYte, a smartphone tool designed to support personalised nutrition for teenagers aged 12-18 undergoing cancer treatment. MybYte will ask short questions about eating, appetite and treatment-related symptoms and provide personalised nutrition advice developed by healthcare professionals. In Phase 1, around 15 teenagers will help co-design and refine the tool through interviews and feedback. In Phase 2, around 15 newly diagnosed teenagers will use MybYte for one week each month over six months, alongside routine assessments of nutrition, body composition, taste, energy needs and quality of life. The study will assess whether MybYte is acceptable, practical and helpful for teenagers receiving cancer treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 29 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Mar 2029
- Lead sponsor
- KU Leuven
- Diseases
- Childhood cancers
- NCT number
- NCT07865117
What you commit to
- Study type: Interventional
- Planned participants: 30
- From Sept 2026 to the primary completion date, Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently on a palliative care trajectory.
Other illness
- Medical instability or clinical condition deemed too unwell for participation, as determined by the treating clinician.
Other
- Presence of cognitive, developmental, or neurological impairments that compromise the ability to provide informed consent or assent, or that impair \\ independent use of a digital tool
- Admitted to the intensive care unit during the enrollment period.
Who the study is looking for
- Written informed consent has been obtained from a parent/legal guardian.
- Written assent has been obtained from participants.
- Aged between 12 and 18 years at the time of enrolment.
- Ability to use a smartphone independently.
- Adequate cognitive capacity to participate in study procedures, as determined by the research team.
- Proficiency in Dutch
- For Phase 1:
- Currently receiving, or having previously received cancer treatment (including chemotherapy) at University Hospitals Leuven within the specified age range.
- For Phase 2:
- New histological diagnosis of cancer
- Enrolled into the study within 6 weeks of diagnosis.
- Currently receiving cancer treatment (including chemotherapy) at University Hospitals Leuven.
Age in the registry: 12 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospitals Leuven (UZ Leuven) Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.